<SEC-DOCUMENT>0001558370-22-005043.txt : 20220404
<SEC-HEADER>0001558370-22-005043.hdr.sgml : 20220404
<ACCEPTANCE-DATETIME>20220404065908
ACCESSION NUMBER:		0001558370-22-005043
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220404
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220404
DATE AS OF CHANGE:		20220404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		22800353

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20220404x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 4/4/2022 10:58:53 AM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 552bb82e-9978-401c-a436-302160823fb3 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20220404" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityCentralIndexKey" id="Tc__f-RTvDZCUeR9vIllJkrNA_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:AmendmentFlag" id="Tc_03sIpntldUuMlv2uVx2EpA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20220404.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-04</xbrli:startDate><xbrli:endDate>2022-04-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_0e9ca0c2_ebd9_4bd2_825b_93ebacf24761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:DocumentType" id="Narr_K_vs8NuQSkyy90X9NYaTVQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_yv9pPLmAm0KY47gB6CSyrg"><b style="font-weight:bold;">April&#160;4, 2022</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityRegistrantName" id="Narr_19NWvUQQqEeDkILN9vkR-A"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_yqtVUXH1L0O01lVHeSWSBA_2_0"></a><a id="Tc_EObbvvWS1Ued3WXmM26n_Q_2_2"></a><a id="Tc_hF2UWpl98UeOHWv4U_YRLQ_2_4"></a><a id="Tc__6suE051iUuSqnJbDV4RTw_6_0"></a><a id="Tc_i498YJeM60eGYViPuFHEGg_7_0"></a><a id="Tc_lR7o8BgtAEC-2ZciJxmHOg_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_g07gPCESekiLN1tCZRbd-g_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityFileNumber" id="Tc_lAeX68PWCECCaV37pKNO2Q_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityTaxIdentificationNumber" id="Tc_HcoQW0KSvEu6SUhB56zABg_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityAddressAddressLine1" id="Tc_ctz8xkZvpU-z_EMtFlheQA_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityAddressAddressLine2" id="Tc_ENelk9m74EiKF_p302WA8A_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityAddressCityOrTown" id="Narr_pgiIOD0WTE-wjHZbcMxQvQ"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityAddressStateOrProvince" id="Narr_KPvhk_Ppg0CTUkZktrtujg"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:EntityAddressPostalZipCode" id="Tc_ZKypM4tWXkqqYktb_E2aEA_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:CityAreaCode" id="Narr_76YT_wRYKkqHGRHX4WXMlw"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:LocalPhoneNumber" id="Narr_vwtjLV7DVEqj-vT6XOGDvQ"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_EIf9uu96vkGFYrgQYSKWNQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_nZNGnwVfw0myrus9V2m6Yw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_H8uGT617x0ica8ZnMj9q4A"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_VKJ3jcJlhUORr5uJ7v-7FA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_RB_jkwJ2B0e4zOQbK_uIXQ_1_0"></a><a id="Tc_z_6ZTFwAMUC5CrArxi3yWQ_1_1"></a><a id="Tc_U1XnOD3noESUbY8cDPJcUw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:Security12bTitle" id="Tc_JZJEx93cOEWzqhl8QjIC_A_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" name="dei:TradingSymbol" id="Tc_ZFINThnMIk26HUB0h-eyjQ_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_fh2Jdsf5VEa4ZikwUzYzGA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_ipcdOj0go0yGgJTscwwuaw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:Times New Roman;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On April&#160;4, 2022, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announced topline results from the BALANCE pivotal Phase&#160;III clinical trial evaluating pegunigalsidase alfa (PRX-102), 1&#160;mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) for the treatment of Fabry disease. PRX-102 is the Company&#8217;s novel, PEGylated enzyme replacement therapy (ERT) under development for the treatment of Fabry disease. A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report on Form&#160;8<span style="color:#333333;">-</span>K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</b></p><a id="a02"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit No.</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20220404xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated April&#160;4, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr><tr><td style="vertical-align:top;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April&#160;4, 2022</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20220404xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/4/2022 10:58:46 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><img src="plx-20220404xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39pt;width:128.25pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:17.76%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><img src="plx-20220404xex99d1002.jpg" alt="GRD Logo" style="display:inline-block;height:48.75pt;width:128.25pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase&#160;III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:7.5pt;text-align:center;background:#ffffff;margin:0pt;"><font style="color:#212529;font-style:italic;font-weight:bold;">PRX-102 successfully met the primary endpoint on kidney function in active control,</font><font style="color:#212529;font-style:italic;font-weight:bold;"><br></font><font style="color:#212529;font-style:italic;font-weight:bold;">non-inferiority study vs. agalsidase beta</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:7.5pt;text-align:center;background:#ffffff;margin:0pt;"><font style="color:#212529;font-style:italic;font-weight:bold;">Topline results demonstrated a favorable tolerability and immunogenicity profile</font><font style="color:#212529;font-style:italic;font-weight:bold;"><br></font><font style="color:#212529;font-style:italic;font-weight:bold;">for PRX-102</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;background:#ffffff;margin:0pt 0pt 7.5pt 0pt;"><font style="color:#212529;font-style:italic;font-weight:bold;">BLA resubmission planned for the second half of 2022</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CARMIEL, Israel</b> and <b style="font-weight:bold;">BOSTON</b>, April&#160;4, 2022 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE&#160;American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx<sup style="font-size:9pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research focused healthcare Group (Chiesi Group), today announced topline results from the BALANCE pivotal Phase&#160;III clinical trial evaluating pegunigalsidase alfa (PRX-102), 1&#160;mg/kg, administered every two weeks, compared to agalsidase beta (Fabrazyme<sup style="font-size:9pt;vertical-align:top;">&#174;</sup>) for the treatment of Fabry disease. PRX-102 is a novel, PEGylated enzyme replacement therapy (ERT) under development for the treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">&#8220;We are pleased to announce positive topline results from the BALANCE Phase&#160;III clinical trial and would like to thank the Fabry disease patients and their families, as well as the study investigators and their teams. Our robust clinical development program, from the Phase&#160;I\II clinical trial, through the three Phase&#160;III clinical trials and the related extension studies, required substantial time and effort from study participants who showed a strong level of commitment allowing our clinical development program to move forward,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;Based on results from our clinical program, we believe that PRX-102, as a PEGylated enzyme replacement therapy with potentially two different dosing regimens, may be a valuable new treatment option for individuals suffering from Fabry disease.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The pivotal Phase&#160;III BALANCE clinical trial has been completed and topline results from the final analysis are now available. This is a 24-month, randomized, double-blind, active control study </font><font style="font-size:12pt;background:#ffffff;">of PRX-102 in adult Fabry patients with deteriorating renal function that was </font><font style="font-size:12pt;">designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The study enrolled 78 patients who were previously treated with agalsidase beta</font><sup style="font-size:9pt;vertical-align:top;"> </sup><font style="font-size:12pt;">for at least one year with an estimated glomerular filtration rate (eGFR) slope at screening worse than -2&#160;mL/min/1.73&#160;m</font><sup style="font-size:9pt;vertical-align:top;">2</sup><font style="font-size:12pt;">/year. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77 patients were treated; 52 with PRX-102 and 25 with agalsidase beta.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-size:12pt;background:#ffffff;">&#8220;This is an important milestone both for the Fabry community and Protalix in a long and productive journey. We thank all of our collaborators for their contributions and support throughout this journey,&#8221; said Einat Brill Almon, Ph.D., Protalix&#8217;s Sr. Vice President and </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;background:#ffffff;">Chief Development Officer. &#8220;We believe that this multi-year study demonstrates the potential for switching from agalsidase beta to PRX-102 in the treatment of patients with Fabry disease. The study met our pre-defined criteria for non-inferiority of the primary endpoint of kidney function in a head-to-head active comparison on both the Intent-to-Treat (ITT) and Per Protocol (PP) analysis sets. These topline results show that PRX-102 was comparable to agalsidase beta in controlling eGFR decline, which is a key measure of Fabry disease progression, and continue to demonstrate a favorable tolerability profile for PRX-102. Combined with previous Phase&#160;III results from our BRIGHT and BRIDGE studies, as well as the results from our Phase&#160;I/II study and its long-term extension, we believe we have a compelling and consistent dataset from both treatment-na&#239;ve and ERT-experienced patients. Given these results, we plan, together with Chiesi, our commercialization partner, to work with&#160;regulatory agencies on the applicable submissions, hopefully bringing PRX-102 to approval as a new PEGylated enzyme replacement therapy for all adult Fabry patients.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">As first announced in October <font style="letter-spacing:-0.1pt;background:#ffffff;">2021</font>, as part of a Type A End-of-Review meeting, the U.S.&#160;Food and Drug Administration (FDA), in principle, agreed that <font style="letter-spacing:-0.1pt;background:#ffffff;">the proposed analysis of the BALANCE study demonstrating non-inferiority to agalsidase beta included in the data package for the PRX-102 biologics license application (BLA) resubmission has the potential to support the approval of PRX-102 for the treatment of Fabry disease. Given the changed regulatory landscape in </font>the United States with the full approval of agalsidase beta in March 2021<font style="letter-spacing:-0.1pt;background:#ffffff;">, the primary analysis of the BALANCE study was changed from superiority to non-inferiority, as demonstrating superiority is no longer required under FDA guidelines. </font>The primary endpoint of the BALANCE study compared the eGFR annualized changes (slope) between the two treatment arms in the ITT analysis set (77 patients). The study met its pre-specified primary endpoint and demonstrated that PRX-102 was statistically non-inferior to agalsidase beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">The median (95% confidence interval) of the eGFR slope in the PRX-102 arm was -2.514&#160;mL/min/1.73&#160;m<sup style="font-size:9pt;vertical-align:top;">2</sup>/year (-3.788, -1.240) and -2.155 mL/min/1.73&#160;m<sup style="font-size:9pt;vertical-align:top;">2</sup>/year (-3.805, -0.505) in the agalsidase beta arm, demonstrating a large overlap in the confidence intervals of the two arms. The difference in medians (95% confidence interval) is -0.359 mL/min/1.73&#160;m<sup style="font-size:9pt;vertical-align:top;">2</sup>/year (-2.444, 1.726). The prespecified non-inferiority margin was met. Topline results in the PP&#160;analysis set (72 patients) are consistent with the ITT results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">The study population (ITT analysis set) was composed of 47 males (61.0%) and 30 females (39.0%), with a mean (range) age of 44.3 (18-60) years. The mean duration of prior treatment with agalsidase beta was<sup style="font-size:9pt;vertical-align:top;"> </sup>approximately six years. At baseline, mean (SD) eGFR was 73.33&#160;ml/min/1.73m<sup style="font-size:9pt;vertical-align:top;">2</sup> (19.82) and median eGFR was 74.51&#160;ml/min/1.73m<sup style="font-size:9pt;vertical-align:top;">2</sup>; mean (SD) eGFR slope was -8.21&#160;mL/min/1.73&#160;m<sup style="font-size:9pt;vertical-align:top;">2</sup>/year&#160;(5.88) and median eGFR slope was -7.32&#160;ml/min/1.73m<sup style="font-size:9pt;vertical-align:top;">2</sup>/year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one adverse event compared to 24 (96.0%) in the agalsidase beta<sup style="font-size:9pt;vertical-align:top;"> </sup>arm. The number of events adjusted to 100 years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Treatment-related adverse events were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta<sup style="font-size:9pt;vertical-align:top;"> </sup>arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21 (4<font style="direction:rtl;">0</font>.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11 (21.2%) patients in the PRX-102 arm experienced a total of 13 events compared to six (24.0%) patients experiencing a total of 51 events in the agalsidase beta<sup style="font-size:9pt;vertical-align:top;"> </sup>arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Assessment of anti-PRX-102 antibodies or anti-agalsidase beta antibodies, respectively, in the study indicated that, for the PRX-102 arm, 18 (34.6%) patients were anti-drug antibody- (ADA-) positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA-positive at baseline, of which seven (87.5%) had neutralizing antibody activity. At the end of the two-year study, 11 (23.4%) patients receiving PRX-102 were ADA-positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment-related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Considering that in the trial, patients in the PRX-102 arm were exposed for the first time to the novel enzyme tolerability data appear favorable for PRX-102 and in line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="background:#ffffff;">&#8220;The completion of the BALANCE study (</font>NCT02795676<font style="background:#ffffff;">), which represents the key pivotal study of the clinical PRX-102 program, is an important event for people with Fabry disease,&#8221; said David Warnock, M.D., </font>Professor of Medicine (Emeritus)<font style="background:#ffffff;"> at the University of Alabama at Birmingham. &#8220;As a physician and researcher who participated in the design of this trial, I want to emphasize that the development of this new enzyme replacement therapy (ERT) for Fabry disease has required the engagement and contribution of the patients and physicians who participated in the BALANCE study. This effort is the first randomized, head-to-head comparison in Fabry disease of a new ERT to an established, approved form of ERT. The topline results of the BALANCE study and the entire PRX-102 clinical program indicate that this novel PEGylated ERT has the potential for a long-term clinical benefit for adult Fabry patients. These topline results also indicate that PRX-102 was well-tolerated and support the potential to switch to this novel, investigational ERT from a currently approved ERT. As a physician, I believe having an alternative therapeutic option would be an important landmark, and, pending regulatory approval, will potentially improve access of Fabry patients to ERT.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Of the patients that completed the trial, 69 have opted, with the advice of the treating physician, to continue receiving PRX-102 1&#160;mg/kg every other week in a long-term open-label extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">&#8220;We are pleased to share these positive topline results from the pivotal Phase III BALANCE study, which represent a significant milestone for our PRX-102 development program and the Fabry disease community,&#8221; said Giacomo Chiesi, head of Chiesi Global Rare Diseases. </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">&#8220;These data are especially encouraging following our recent announcement of the positive final results from our Phase III BRIGHT study of PRX-102 in Fabry disease and bring us one step closer towards potential approval of PRX-102 and launch in several countries as a much needed treatment option for patients. <font style="background:#ffffff;">We believe the totality of the data observed suggests a favorable benefit-risk profile for the treatment of adult patients with a confirmed diagnosis of Fabry disease and the data will be included in our planned PRX-102 BLA resubmission to the FDA</font>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Fabry Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Fabry disease is an X-linked inherited disease that results from deficient activity of the lysosomal &#945;-Galactosidase-A enzyme&#160;resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>) in blood vessel walls throughout a person&#8217;s body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the &#945;-Galactosidase-A&#160;enzyme, which is normally responsible for the breakdown of Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>. The abnormal storage of Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>&#160;increases with time and, accordingly, Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>&#160;accumulates, primarily in the blood and in the blood vessel walls. The ultimate consequences of Gb<sub style="font-size:9pt;vertical-align:sub;">3</sub>&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure &#8211; particularly of the kidneys, but also of the heart and the cerebrovascular system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About PRX-102</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">PRX-102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant &#945;-Galactosidase-A enzyme. It is a novel, PEGylated enzyme replacement therapy (ERT) under development for the treatment of Fabry disease. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX-102 has been observed to have a circulatory half-life of approximately 80 hours. The Company designed PRX-102 to potentially address the continued unmet clinical need in Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.&#160;Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;-Galactosidase-A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">expressed recombinant PEGylated uricase for the treatment of refractory gout; PRX-119, a plant cell-expressed long action DNase&#160;I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Chiesi Global Rare Diseases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 7.5pt 0pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit&#160;www.chiesirarediseases.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 7.5pt 0pt;"><b style="font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 7.5pt 0pt;">Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years&#8217; experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people&#8217;s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group&#8217;s Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. In 2018 Chiesi has changed its legal status to a Benefit Corporation, according to the law in Italy, USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world&#8217;s largest B Corp certified pharmaceutical group. B Corps are global leaders convinced to leverage business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has set forward. The Group is committed to becoming carbon neutral by the end of 2035.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">For more information, please visit www.chiesi.com.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:always;width:75.81%;border-width:0;"><div style="max-width:100%;padding-left:12.09%;padding-right:12.09%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;margin:0pt;">that might cause material differences include, among others: risks related to the timing and progress of the preparation of a Biologics License Application (BLA) resubmission addressing the complete response letter; risks related to the timing, progress and likelihood of final approval by the FDA and European Medicines Agency (EMA) of a resubmitted BLA and of a Marketing Authorization Application, respectively, for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:7.5pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Investor Contact</b><font style="letter-spacing:-0.1pt;"><br></font><font style="letter-spacing:-0.1pt;">Chuck Padala, Managing Director</font><font style="letter-spacing:-0.1pt;"><br></font><font style="letter-spacing:-0.1pt;">LifeSci Advisors</font><font style="letter-spacing:-0.1pt;"><br></font><font style="letter-spacing:-0.1pt;">+1-646-627-8390</font><font style="letter-spacing:-0.1pt;"><br></font><font style="color:#009ec2;letter-spacing:-0.1pt;">chuck@lifesciadvisors.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Source: Protalix BioTherapeutics, Inc.</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:12.09%;margin-right:12.09%;margin-top:30pt;page-break-after:avoid;width:75.81%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20220404xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220404xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  T *L# 2(  A$! Q$!_\0
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M@F]^R5;Q^,?C5\<?'FH#SM6&O-HELTG+6]M%G"#T!"Q_]\4 :=C^S7\4O%L
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M?Q;^)-AK2C9+X8FU>;^UDN/^> MA'O9\\# *GKG'- 'L?CG]HO1/"GPO\/\
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M+6[^(/@+_A&_#=S-' VM:=JJ:A%8L[!4^U*$1D0L0#(NY02,X'-=-\1?BO\
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M,#% ';A%!S@9]<4AB4G)Y-%% "3V\=S$T4J++&PPR. P/U!IT<:Q(J(H1%&
MJC  HHH  @!) Y/6@(%! XS110 *@4\<5&;2$W G,2>>!M$NT;@/3/6BB@"1
MD#')YHV\#KQ110!%%9P0&0Q0QQ&0Y<H@&X^_K7D7CQ0O[37PF Z#2M<_]!M:
M** /7H+."V+F&)(BYR_EJ%W'U..M2LH=2K %2,$'O110!';VT5I&(X(DAC'.
MR-0H_(47%K%=QF.:-)8SU210P/X&BB@!ZQJF-H P,# Z#TH$:KNP.&ZBBB@
M"!5P.![5%%900-(T4,<32'+E%"EC[XZT44 /EMXY]OF1K)M.1N4'!]>:>!@4
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20220404xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20220404xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !B 0$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZY+XD>+
M3X6T)C X%]/\D/JOJWX5U<LBPQM([!44%B3V%?-WCWQ0_BKQ!-< G[+'^[@3
MT4=_J>M F8-Q<RW<S2SRO-*QRSN<D_C45=M\-/ J>+;V:6\5QI\ PQ4[2S'H
M :])_P"%.>&O^>$__?\ - K'@%6])TV;5]1M[.!2TDSA1@5[I_PISPU_SPG_
M ._YK1T/P#H?A6Z>^M86214(\R:0L$'<\]*!V$34M!^'=AHVE7M_;V#W<HMK
M996VF>8C.!ZDUT]?E!^V;^T3<?$[XNI'HETT6C>')?+LI(G/[R96^:7@XZC
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M_!%7P@NG_"'QAXA9/WFHZH(5?'\,: 8_,FOT>K\=_P#@FC^WS\/?V?O >H>
M_B)<76B6CWCWEKJT-I)<PC</F618PS@Y'!"D<\XK[A_X>A?LR8S_ ,+-7_P1
MZE_\C4C(^D?%GB6R\&>%M8\0:B673]*LYKZX* %O+C0NV,XYPIKX9_X?1?!3
M=M'AOQL3G'%C:\_^3%>>_MS_ /!4#X<>+_@]K?@7X6:A=^(M1UZW^S7.J_8I
MK6WMH6/[Q1YRH[.0,?=VX;J>E?G3^RU\*KSXU?M >"/"5I"TPO-1C>XP,A+>
M,^9*Q]@BM0!^]O[3WQ.C\&_LH>/?&2B6R?\ X1R:6V2;"NDTT6R%6P2 =\B
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M$!XS@UK?\+ \1_\ 08NO^^Z[RY^!&Z9C;ZMMBS\HDBR1^(-1?\*'F_Z"Z?\
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MBOU"_8?_ &#/#_[(FBW&H7-Y'XC\>:E$([W5Q%LC@3@F" 'D)N'+'!; ) P
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M0K/')"P99(VSAE(ZCBOD'4/AQ_PE/Q:\4:/!=:?;-9W,EQ=7EYX LVMH5?\
M>*#<L?G)# 9QDGK7HFD>*?[#\1Z;):&,6=E&EHH@A6%'C'!(11A022<#I7G5
M^31K<_-L_CA;4IT[>T:3=DU=-7NU9+7RTMTV/HRBLG_A*--_Y^H_^^J*Y3Y
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MLY\Q1CA\DG<.<UB>+/@]X$\>:E;ZCXD\&:#KU_;X\JZU'389Y4QT 9E)Q[4
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M'\M?[H_*BJ&.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L7Q=&KZ%<EE#%5)!(Z&BB@#R?X<V5O?Z_
B)]JMXKG!)'G(&Q^=>X(JH@50%4#@ 8 HHI(2'4444QG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20220404.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/4/2022 10:58:57 AM-->
<!--Modified on: 4/4/2022 10:58:57 AM-->
<xsd:schema targetNamespace="http://protalix.com/20220404" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://protalix.com/20220404" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220404_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20220404_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20220404_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/4/2022 10:58:57 AM-->
<!--Modified on: 4/4/2022 10:58:57 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20220404.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20220404_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/4/2022 10:58:57 AM-->
<!--Modified on: 4/4/2022 10:58:57 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20220404.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20220404.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637846667375990476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637846667375990476" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637846667375990476" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637846667375990476" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637846667376000494" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637846667376000494" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637846667376000494" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637846667376000494" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637846667376000494" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637846667376000494" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637846667376000494" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637846667376000494" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637846667376000494" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637846667376000494" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637846667376000494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637846667376000494" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637846667376010481" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637846667376010481" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637846667376010481" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637846667376010481" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637846667376010481" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637846667376010481" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637846667376010481" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637846667376010481" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637846667376010481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637846667376010481" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637846667376020469" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637846667376020469" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140560464531336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  04,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>plx-20220404x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20220404.xsd" xlink:type="simple"/>
    <context id="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2022-04-04</startDate>
            <endDate>2022-04-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc__f-RTvDZCUeR9vIllJkrNA_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_03sIpntldUuMlv2uVx2EpA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_K_vs8NuQSkyy90X9NYaTVQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_yv9pPLmAm0KY47gB6CSyrg">2022-04-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_19NWvUQQqEeDkILN9vkR-A">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_g07gPCESekiLN1tCZRbd-g_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_lAeX68PWCECCaV37pKNO2Q_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_HcoQW0KSvEu6SUhB56zABg_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_ctz8xkZvpU-z_EMtFlheQA_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_ENelk9m74EiKF_p302WA8A_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_pgiIOD0WTE-wjHZbcMxQvQ">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_KPvhk_Ppg0CTUkZktrtujg">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_ZKypM4tWXkqqYktb_E2aEA_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_76YT_wRYKkqHGRHX4WXMlw">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_vwtjLV7DVEqj-vT6XOGDvQ">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_EIf9uu96vkGFYrgQYSKWNQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_nZNGnwVfw0myrus9V2m6Yw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_H8uGT617x0ica8ZnMj9q4A">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_VKJ3jcJlhUORr5uJ7v-7FA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_JZJEx93cOEWzqhl8QjIC_A_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_ZFINThnMIk26HUB0h-eyjQ_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Tc_fh2Jdsf5VEa4ZikwUzYzGA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg"
      id="Narr_ipcdOj0go0yGgJTscwwuaw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( &,WA%1ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !C-X14)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !C-X1499!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20220404x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20220404x8k.htm">plx-20220404x8k.htm</File>
    <File>plx-20220404.xsd</File>
    <File>plx-20220404_lab.xml</File>
    <File>plx-20220404_pre.xml</File>
    <File>plx-20220404xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20220404x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20220404x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20220404_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20220404_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20220404.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20220404",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220404x8k.htm",
      "contextRef": "Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20220404x8k.htm",
      "contextRef": "Duration_4_4_2022_To_4_4_2022_I0rRHkhmD0eMbqqGjiq2qg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20220404",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-22-005043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-005043-xbrl.zip
M4$L#!!0    ( &,WA%1<P&C,P@,  -(,   0    <&QX+3(P,C(P-# T+GAS
M9+57WV_;-A!^']#_@=.[?B9.:R-.D:SM$"#9@"P#\E;0%&T3I4B-I&KGO^^1
M(F5+EAUWV)ZB\+[[[KOC\4A??]Q6''VG2C,IYE&>9!&B@LB2B=4\:G2,-6$L
M^GCS[I?K7^/XY>[I 962-!45!A%%L:$EVC"S1L^RKK% CU0IQCFZ4ZQ<482F
MR57R(<^G29%?O9^@./9,=UB#IQ3(419)WEE^\ZQ2S-!E>ID665&@/)M-/LPF
M[]'M8P=\!)5+]B9RJ\N9)FM:862P6E'S!ZZHKC&A\VAM3#U+TUI)@SG;)D16
MCB6[S"XCA(U1;-$8^D6JZA-=XH8;*(KXIP&PC0RUXM26H@?8,T-QA9Z!@B[4
M9K-)-A>)5"L(E.7IR^/#7TY< )>4=>#M0O%$4Y*LY/<4#%9;'H"P.2N,ZPZ\
MQ'KA>+W!@>,LCR\Z%ZU,;%YKJ@^=.M.(&Q JR<>\@F7$2=%E+VF7BT_[*@5K
M5QTPE*:?L\=-TM88H*11"KKS=;Q P=JKTI8?57&1OCPP\2T@!69$CS,[4X_6
MENM(33K32%&(;(11Q_2WQOXF&W54_S0%ZYZ@42DC(C@D?:(HUKR TQG@=$O6
MXX*M95#L(;5O]7PZG:;.VNEE9)P4#,,V/]*RP3*2HJ K.T-.E,[N4.IAG293
MJR.BP-)3=<9H"&>?O7WV8R:TP8+0_3/!3NS1$%\:-:A2SP?,J37;%#);J5TB
M-=^^-09]&XBF*L9.:9%!(Q@J-%MP&EL85=C =:+CPEXG8:S5BI)S-F6'W.VF
M>7LG303#'B$W[K$0D(G5X-;":ETSL91^"19M/\ZL^S/4!MF/OY_NQZOA@GSR
M%U_X>RO*S\(P\WH/M*IR 2/$(,.SD)V0(*6D2R:8DYU!9AF*42#8_\2B1"T;
MVJ.[3H<<0_H&;MP_Q8W[AA)KX'*>=@AZ;P\YY4DP)PW_%XX[9<?]_&K8D\%6
MA<GT1)?(#9.9;>IYI%E5<WL6W-K:W3S0UW%HX:^0;0*M%!"6_L3A<GL]+)"/
M&RBP(@<L![/.ME!-E6$PHW93-?VOLN)X\;-9@0OE_T\ZU^GPC/F5_EET)Q$R
MD\H@<? 0.S7IVC?<@R2.[(2+_:^;J+%=BO,"+H<$0@>]IV6,OT'.%! <;.3)
M3\8\?.N-!=7'X/;#]L=AJOZ=ZN+NQM/86+I=:*,P,>T@@X;[>AZZ;5IW<<%%
MJN#WP[VAE3W%D$0#,&8:Z_&[DDT=@ P@\,[V)//(J ;@ GY X(5MQ_;_%@NM
MQV3Y[,*4C?+3UN;8-EI;J9L?4$L#!!0    ( &,WA%2<E:R;H@4  .4^   4
M    <&QX+3(P,C(P-# T7VQA8BYX;6S5F^]OXC8<QM]/VO_P'?=FDRZ$I.W=
M%;4]T5[O5(U>JX-IITW3*20&K 4;.:; ?S\[B8$$FY]=9-ZT(7[\^/N83YP$
MPM7'V2B&%\023,EUS:LW:H!(2"-,!M>U2>($28AQ[>/-SS]=_>(XWV^_M2&B
MX62$"(>0H8"C"*:8#Z%+Q^. P"-B#,<QW#(<#1# 9?U=_8/G7=9][]W["W"<
MW.DV2$1/2B"U].O>HN4N=Z6D">?NN>LW?!^\1O/B0_/B/;0>%\)'464?;U7&
MF/S;E']Z8D@0<4G2G"7XNC;D?-QTW>ET6I^>U2D;"(.&YWY_;'?"(1H%#B8)
M#TB(:B#TS23=V:9AP-.Y6ND^Z[%8&9RYB[&,"OG*43)'[G(\WSGSZK,DJN4E
MRN8=!E%RV1KQ18=5\86;-2ZD:]9Y?._R\M)-6VMBX@#RJ0MZ*&Z++4B;FGP^
M1M<U-..(1$B6F^YE-$8;RI7-[M)9>M.P8!C+B:5,^0T9ZE_7QO',D>]JX[QQ
M+B?GC=CQXU/.7XM$]X1C/G\@?<I&Z=O2ZB6<!2%7-FGQJ<^NW>04[33O[B*)
M'*/%BG$"%JH:Q.:6V<D5;D@%;6/NI(ZJ>Y_1T5X)LBKH[GU^Q+WX\.2%V PE
M=,+20V9W+%;3[OF&+4H7'>6*A8CS1V>/+#=J$ A(!-DPL#(._*U&^N<J*W0O
M?F4!B3H<$Q36!_3%C1"62Y4G-R3=Z6'_1KQ8).X*Q]*$:)HM)=441!)9;K.0
M/&.)1Q,FW2J$Z!DQ3,61$WT2I],-(<NZ$\!*&ZW,5T%D.6CZ6H\F+K,5RUH$
MTK@"^+(5]#..T=?)J(>8)K-&8C%RID"*MG*[I: 9RSR4L?Q4*1TALZR,KF]H
M@.4YF?"OP4BWLAEDUE.F#U8DK:BQFC9#J4<2MW0%:5L9=0_BKIB-*4LO"SM<
M+*=W=$(XF]_1R SAME[6,[E3["*B&[M83>QNE1\)<&&0MY . Y1!/A3(L2JC
MNAO,'B)QJ8#[./M<8\MIVZRWGN0M48L,&\16T[NMYB.Y%?90]*_ZQ-^*(C%K
M2?ZOC0GRC).AUUH/Z8:(14 U0JOAW%3OD6#FGF_5!DAW>"+5K:+KX?P])L(_
M33#]7<'T3PQ,_W\ <\EE=TJKYC*]Q'ABSXR^8!*:+U:-\E.ATQ!4"VA)>PJ,
MFDI^+4P7EZ)JA*I!O1.;3ZQ+IV3;5!24IX+G>CPMF4O9*4"IJ?:U>)36$D=I
M7C6*SS3A0?P7'F^\O3>(3P5(;4@MDP7E*6"I+_BUR,S<0=A7=;LNCX460X$!
MQU*SQ0#J@BCD5MLLA4Q;XJ%8I0N<=*N*(OGT2OP\I,3\]8Q&8C%-ID"*J'*[
MI509RSR4K-004L?J/J7YDV'.$;FCH]&$Y)\1)9JT)IW%G&V,IF#3BBPE;G.M
MAV*7NT+1M@+T.C3&(>:8#![%/0S#@2ZS5F0Q=.90BKAUA:6X;2CT4-:6EJ \
M*P#MF2$)-Q)O7/J$D'P(DCWU^]ISZ4:QQ>!M#ZD -"LM!7&'@@\%4E@[X8HW
M9.:0NE>/YD.23!#;"U!=E]/!U!C8 .N:_C20-9?]:N!F0U3-;P>%$W'],/?\
M7A?S6'>;JY%8S*<IT.+L76JWE#]CF8?REKH [8/G_]K[#91_!8AU62!_V=*9
MCWI4%[7<;C%<VBB*K$*CI5CI:SR8J<P-,KL*5ZO[63@4)2/#LX@&F<5@;0I6
M7KE6-99BMK'4@^\]<E-0KM4^BW@_0FP@:/_"Z)0/Q<7!."!SXR?B)K7%#.X0
ML_@UA59J*9&[5'SD%Q7*'#)WR.TK _1.7$6R('X0UX^SWY$9S76=]5 :HA5Q
M+(FL!M%4ZY$(YK:0^H(PK@"^EKA[B>0=S.<X&&@"E]LMADT;14%6:+04+GV-
MAT*U< -IMXK2E;L<N2VVY$^^\UUY[YO_ %!+ P04    " !C-X14(C(Y":,$
M  !&*@  %    '!L>"TR,#(R,#0P-%]P<F4N>&ULW9I=C^(V%(;O*_4_N-GK
MD \R,$$SNV+8V0IUV!G-4'75FY5)#%AU[,@Q _S[VB%F^4@@M&IH<@,A?G-\
M7C^.24YR]VD5$?".>((9O3><EFT 1 ,68CJ[-Q:)"9, 8^/3QY]_NOO%-+\]
MO#Z!D 6+"%$! HZ@0"%88C$'8Q;'D((1XAP3 AXX#F<( +_5:=TZCM]RG4[W
M!IAF%ND!)O)(1D$:TFTYVY9!%I71'O LSW)MUP6.W;NY[=UT07^T%8YDEE-\
M5DDP_:NG/B:R2R#MTJ2W2O"],1<B[EG6<KEL+=LMQF<R@.U8WT9/;\$<1=#$
M-!&0!L@ 4M]+TIU/+( B':N=PU<33G2 MK7MJU"A?IE:9JI=IN.:;:>U2D(C
M2U$UE^A$RU4K/J'?\;+1'\7/QL#Q?=]*6PTY>@#<<4;0*YJ"=%]/K&-T;R0X
MBHF*E>Z;<S2]-V*R,A4!V[,]9>3#YVR>Z.\^#1^IP&(]I%/&HW08#:#"__XZ
MW*82<R8@P:M6P")+-5KEXJ2V2@V8M?$5<Y3(:.GA3[(Q,Z.Z_/?)[(P56@E$
M0Q1N]V*A>K!MV[>!"72@W4U(0[")"OZ9Q]2A]$A8L)<+4;.7\3/@Y([OI_SU
M)XG@,! Z#($31-(X)0^S+LI/V4VDW]1K@H+6C+U;(<+J?'?4ALH^/7<^R!_;
M%,8RXD&&A\W?.^WNK=?I=+KM[HWOVUZWLY/<[@3I\_U$(0]T;+FY-V>.L60*
M*X9<QC.#.2;;V3#E++IDZ+(D6$DSC(>(RW7= (M$ILAB%0V2BA"\((Z9=!-^
MEBOZ"19[NL9 .>\JH^-62V=CY LFZ.LBFB"> ^90LIM]1ZY<GN_5BTDI0QF.
M]C5PO*(95JE3\15&>>=*GJPA6$J8RM!XUT SE-?#/&8\=?(FQQ,-V((*OAZP
ML)C4R:,: NYRCQG'FVMP',/5,)0^Y4W#YAK^S/)7H&\(NTO<9=0ZUZ#6#T,Y
MI$GV)2_4D5-(+$?;$%IEG66DNO\/4NX%I-S&DLIWEI&ZO2*I=,5^YB^<O>--
M:> DK -YLWB5,9<A\Z^(;" WG_F8+>DY6C^4S0)UQI>^X;6O".F%)0*2/W%\
M\@(Q3]PL5.>M:5H5UR?4'.IS! OX[#;7GLA9,YI!Q54(54@G+W-&BZL0AY+:
MLRAE2/.HN SQ!\="(#I@4;2@V2U!D@,E5[=OQ+&]6Z=>9,J[TGB.2Q$QQTR&
M6:<%O?^4U1LC., "T]E(7K5PK'H_ G4LJCVEDI8THN,J0W6(7CA2DPG):\FT
M0*\> ?'GZ31WH2L6UQ[9A=8TNN-2P]70#9-D@?A% (\.:1K&<@8US.-J1(5+
M)0H6JB?'G8S5@]>\A?) 4GM8I0QI.!47(,8<JG=+WM;1A.7]:^VUUY[$>3<:
M0\5%!3U%'E?!'-(9*GCHE">K/932IO3CV>-:PH_URZFDL/ 8(3Z3$^E7SI9B
M+E?B&-)U864A5UU[;)=ZT_0JKBULTAQ(<QR2H?R#7/V&BE$=Z!H"J8PKC:?B
MLD-?.@J5JR\$SG*P[+7O)^[:7L>O%X[S;C2&HFK#G77XGIQZI]+:#!O>O&[V
M\6]02P,$%     @ 8S>$5$OEAK 8%0  :)X  !,   !P;'@M,C R,C T,#1X
M.&LN:'1M[5UI4^.\LOY^JNY_T.7<<P:JQHZ7[#"<"B% 6!+(PO8E)=M*8N+8
MQDL6?OUMR79P0D(8#@EA!MYW(+%EN=7=>M3J;DE[_QGU#30@CJM;YJ\?(B_\
M0,14+4TW.[]^-!M'7/;'?_;_@>"'_4)H[W\Y#NFW![5SI%FJWR>FAU2'8(]H
M:*A[W3QJ6+:-371!'$<W#'3@Z%J'A(_D^#2?%<4<+XGI3 IQW'Z\V@/L0BV6
MF0]+B[PX6Z08OHH62B:2"4F0)"0*^50VGY)1X6*V?%#1N:XXV!E'#<U#S<*$
MCJP\_Z$Z<0:Z2M"II:#R81ZE4I*B9"7"Y7*9+)<41)7#23G-R0)4(F0EN:W$
M:X(_>UT/N L<-MV\1O1?6UW/L_.)Q$AQ#-XE*M^Q!@FX05LA;@4%)X6&PR$_
ME'G+Z23$7"Z7&-'*PD)YVQA-"MJ.Y6%#'_&JU6?\$))",BIHZ&9OJDKV;EJI
M) AR@MY6@.M1\=&+\E,DT+N3HE"1YDVW*:PWE0AN3HK.;144%!.W%^=UM4OZ
MF---U\.F.B%%'WD<\&CJR8AGN@F4$"JEA.=@TVU;3A][(%FH5$QQ0I:3Q5@]
M\QFPK!*)D]+/E2QBHBC'*HJ*.Z2]D.GI!-R-,U%_13X3INSO=0G6]O?ZQ,.(
M%N?(HZ\/?FVIENE!'^2\L0VL"[_]VO+(R$L$&I/8W_-TSR#[>XGH;U"78FGC
M_3U-'R#7&QODUU8?.QW=Y#S+SLN"[>W"6Q-P>ZJ,IKNV@<=YTS()+:"/\K0V
MX@0?=4TC)OL(!2H #XZN!E2-O!KERJ'O,":WDO ?U=96PWK^7!:<VDFOVS\4
MR(7R^'C\H#]*CYTM9.(^?3?1\R43&C$N0B,=;)1-C8S.R'@+Z=JOK8;::K6Y
M6F-P>%]LDEIN4#:,TYY3*;2DEKBU+X"^ ?NEK+B7F*)OE>06 " U"I)'!NY,
MR!1DMVR;GJ$U_0MC(/G7(ZED%UHR);.-#9>\H# QS5Q0(>( 4!-W?X]VRKS+
M.A&0C%@GS7>9"@),<!$B\"-7VPKO4F7YM>7J?=N@JI68KB)X6_P5[*MK^0[[
MQI0V'W*)->E=7(HJ(DRBT3==H]_;.G$0(XC,!8!B^6Q:H+,/[T>7IFNW@9N6
M%GV#ON5XAS">[%,Z.2$)_T?//=^;D*DM*!K=B;Y'+TE,,2KBZH2-B5C7>='-
M^GC$#74-QE-HXK]V;:S1(9DS2-N#*[R<>K[FZ)WN\T7+U:DDX$4&B&3 ^FBL
M7M4@V,DKEM?=G7W%BR?[@ 5=$M0N\]D $.RHIC8TBVOCOFZ,\S\:>I^XJ$*&
MJ&;UL?GC9W %_KK C/:/75;:U9\(O PJHH YJ1N^1VT!PCRK/W6)HA']3GG(
MP3C7,?,J")4XNXKE /,FS_!0,7(M0]?0/P7V$Y5@@#;G=H!W^1#J7&JUQ!L7
MD LWV;=A0*UB&5KXX.3-$I09Z*ZNZ ;H6MA/H<I__S,K"?+N7H)6#4*V/XI]
M+WGQEJ;(']L4S+I^2R Y%0NJU"**EFLE%4UJ9:64TLK)1,%J6TIFTB+%&+RN
MQBM3;XFW=6N_62DW2H>HWB@T2O6]A+).H;Q&5[U4;-;*C7*IC@J50U2Z+9X4
M*L<E5*Q>7)3K]7*ULD9B$?V7#/XN(_P&NUWHI9YE_D2'?)%'DI!*YB;$QI#G
MW>1*M.?.Z"F[$H,G7LR1_AP(B^';- Z":O8ZCN6;&J=:AN7D(TR(@]*+ZBB0
M"'P:7A54+*5XJ#E F< BBKB(L.]9SP94\/OS]>RH6KOX]S]ANK++1+0ZN^<P
MG!LVF%E*@:*"':=UUAJXV8I_5>^-QSGA-E>YPXWKJR5$9[FS0*%F;:(5*ECR
M6\'>I6  8[52I8%JI<MJK;%!"'OI.ZZ/30]Y%LSL5<KVH".(,K(<)*:VM9W@
M@M5>-]:FWX:U7I=0TGT'E 8(*(W4+C8[!!54#UEM).;DY(:.$M0\IB36B&TY
M'MJ.OI<P&,C$]5!I0/U(P6VB[>312N IF.'_VM)'7EX#$OI08U?#XS'8Q,2<
M!U^7S)0O!09^#,?&@YQ]>=XO](6SNV2F<Y NUL=.9PD7"K:C&X&.)7\B2NG:
M8>UO'3>3;T"/5?LL:J2CN]33Y%7@3DR9Q%SE9M"\NGHLD<->^;R2&_1J7&$9
MGH5>/W2@6XTN<;!-?$]7W9^!@I5-E5^H79^/QMNE$0;4HBRB..!,6(.PBUR;
MJ'02KR'=1+KG(L Y@ 5GY]NL7.&H_Y899/8%Q]XQ8=249))(FMS"22W;2J9S
M0@OG--Q2I&Q:2+5521"T<,*((X?9^-&[;MZ>B.="51"-ZQ-2OZD?4+^>,%NR
M5%64P>"F+C:))M_<]B^DM-FZ@I+2;,GND=2\L8U<MDFJ)S>#9+-U5SNG)9.S
M)5MIUR\)*5%O^O5'\U0YO$[6&L-6^N7;]60N>W=*+M(".;Z[UB_]HY/2<:>5
M>5G2J&6L[$''*Y2*G'2OZJ>C_DF5EHS>[F'%(!.]"AP9H%,&MEV2CS[$A0A6
M1*1FU+43NH(C>3'/$=.>\$+@-F)7IKQ+0LSW$I2A5Z8UWG,BPF)Z3:]KT?4!
M<0"-L!$"1* M82URDL^E_A57N/!]D?+%.E2L?@OJ;!O6,-*QZ#LW!/#+*P[!
M/6X(?%KJ XMU]DE1K+B6X7NS77M]74M\>S^*]_V$I[W"=@"6"%)X(?V)+'_)
M9X9Y+Q3KB_-[2LT!Q7/9;S7_5O,_6\TIFLO?:OYQ;$]X#AUA/VPT78^UO\*Y
M.DT#H/$XC]B.-:!SANG)>C"]@AF/Y=A6\*XZ+5T$.]QSQD5+(Y/(:T?(="Z+
MI3KIZ><5T2O>UQ2-Z[1$9J"]ZL( [1MBARR<5'T41'W^Y"R80;[\/9E^?>0@
M^#6U<U;YCG2#0.T*<2::9A3(;3I[>5,L%8OX6L[89Y6J= 6:)BUAOR"(G"S+
MJ<RWJGWL0/1GJ%H#C\IAFH/*JIO1NQ/5NKH1SNJ#DI^N-[L'J?13X8 B7'*)
M+-(I3D@GY4Q&?EWQON;X]*HWB@T7- Q@>5WBH ??T5U-9T$"Q@O%H5E4KU5A
MM9$>'X!VWJC!F]997Y@S\6:^U:)Y:XLW8VQX53.*5K^ONS1I%%&,1T%G^Y;N
M\A9O"!R_*MURK8Y*?=NPQL0).OHKI4,46%9L&IQ1Q>)GM.5KXN=:@>$OZ2R;
M:"E_RWG%<MX07/RP5G]-.%NUE5[0-(>X;OCG7#>).+'05>\I.^K=#^PF]]0J
M77A'1I=<%> -RWP0$FJ:.EO#XHW1I8&?\!\R18PKXU^!K'\\D/X5N/D-DQ\/
MD]($)DL58O1R_4RRI)\=M6Q9D&X*V4(KM10FZ[X.LWE1$+[1\1L=_Q(I?J/C
MGXN.1?A8=1K6T(PE#=H=O5P]%&X:)6[X<'*OJ!>CJ\&R3/H3K/:(Z<+ON=#X
MVJ,_5Y.2NZ#)S"%;=2X=:Z"S-<'/*P@N!]U>Z]+N",5&LW??\QS/?UB6>5LY
M_1X*OH>"C93BW^-Q6!-T7%JNAXU[W9Z*^]^?C>V+I'=SVWM\O.MY2JLDX5*A
ME5X:%1,R:4'\ZP)B(2]I;K;M  +K-C80&1'5IQDX<+FMJ\3]$\(@WRCZC:)?
M"45?[;: >HC"WKR(4X(EE'^=U0)K6L$F"I,E;&'JR6L<?E[#0RD6,[LN\HA!
M[*YE$F2RV/!/F@A@^%0S$'8(AI%.(ZLVGND4H0 O>Q[SF+&<2=\U6L/:W5GO
M\>2X=G*;O+F],(;+O,P+QKO7GN%6W+YS"WKE)>5R/-N%M7$P]![.KS.'UZ7'
M!V[02-]6CP^73H32N327DY.I35XB=60Y0%"X1LIA"9'P%0<C,VA9&P7K/P&]
MZ!P)&=CUD,.64/*K7RH5H,!?OU9J%D.*7:+V$%VIBVW;L<!XHIE%BC5""C&L
M(94:O4EE&\!-ECM#;4!#0 O=!>CPB*F!2#T+I-KW#0^;Q/)=8XQ<:+_;'K/'
MPP<L!50K2#.P@GIC"^F KU1=S'%TKVT90 %]CJ;1ZC2GQ47;>_HT<-//>9TN
M+52A.2ZA6Q'MHV-B$@=,P+()M?LL,0H5>(D/6K63_\ ^LYBW*\\Q5BS+4#!P
MR0.!Q>'GQM$]$ Q-!O+-,+/#C6%0J=S.^7XN/>@=']TYG:N[^ME-Y6K>P!AQ
MI4XZ%D'-,JJ/^]#A?[#A)Y=))I_'P&E46I0I&9(&W(C1ANS8:O>:;Q"4E%*A
M1LRL(J>+Q[?%#"H>U9 D"SP4W/G#I5FW0+FA]6;G CHG]% C)DKSOG)L#J_;
M0Z$_=GPW=RWUTW?#M8CRF2[4#PE[*4@QB3E1BLER:AN B223 A^4_-.%>>D0
MVBWI1F5LOQ$*GTZUW9ZR$4ZR_G$C+69& G20[+UY\9![3!;6(E2@CU-C!$YW
M5'>>@#5.VE9VWB;BH.QJA+Q)<BV[KD^<^=*]/CN5']13H]NLUIR4?YH9<)FC
M396N3+CDMOHVZ89E5R?=KSEO6V8YQT:WP!XB#EA4]L(-8&@/BK9^81(!0>0_
M>">5M:VN)YD,R0I)W-(D26XE,U*NE9,R6DM-*VU1;BLD2>2MF;7HM8/60V]X
M*AT()/E4O5+.6G[Y]BI<%#55\JF5OF\<#0L7S6*JZ!2<D2Z/;VA)<;9D4[PU
MJX>R:97J3>4NJQY>GJK-8;C\Y2/7MZ]Y\7I26.0#0BD^W XG^#0SW?GDM8_O
M7-TIYOA<[J]JL?P'M?@W(Q/)R4SZ#9MJ!EN1+KX?;DOZ^JZ<\VXOX'R2ST6;
M3M%/:_.X-NB>R70.3;#:1:J!7?=W7<=A)WHS:_\8UCF8N4$#*VO;W?EMG_M?
MRKA*N"\24SD2V8<PKQ]V=;CR;-7\3A#R.7ZSIGZ^84Q=H7LZM#C'HJ0PN)B$
MG4_O3TNCG*Q62S=/CUTC>_50+K;"?8OH],:B9J"E]GZB_Q-X01"1C1TTP(8_
M9P?PWPC0?1S@_#TR#,$JP*KGO(&C<J71-2_*/2E]TCP0NAP9/UP%&\I?GM_^
M5U+Z.'3[TZ4TZS6@D/AR'XBH%T83ZN=M]D"0[:YTJKGMU'4))^_UWK#Y=/=T
M7 CV!:O<U4NHP(C%YI(\C[\SC#KC^<M.'']E4Z/.#H*4,5)9[ .*]F"<(FPE
M]4Q,0G<1M)  8SO4+N@XUM#K4I^)3>,4V$4::>MFL/$?=9>$FV4*J2B&,>.X
M#G8]E2=>$UH^L\O<V$)JAT;-GFL!;.:D.?7,VT9UMD+JC*&/[_"K<7&PGOV*
M>[6T@&.?YYX+4JXBNHX96<6 JIAG3K=5K?H@="QA?-PY;;CJ<.CCCW6FK\I'
M4VZ_HJHTQC]7[_478;@N:#4QB$H/+3(MYGWR7<)*@:C"8!\]?D8/ C=LPUDJ
M!_8N8TQ?3L]58I$\$]H"=QP"G1^>@[Z"396&";"JTLUN:&%Z8(R&'<T-PGS:
MJZXO>1M/N[[BO8%'"^4TP]I02M)JH6<Q1,X]V6"M /F. RVFQ_UYYU.\?=*R
MD#-SCZ_XI*'CHY*V)G1-G47T>T3&Y?56+1/^"U[&7#/_\X\W94'$3FH)Z928
M$G4(%WB/<!L,KSPVAGCLAA9E)L?+DV2(B8+(P6A"SX=!L<_/'J,-.W?FP\S4
M%\):/,*6/1(E9/""N"C<L^AWE1D[;!/SP#GT=9S;L4FC"$;.%]@\\3W[0F:S
M?#;S%=NVTCG';">HFNCE'O4_T<*MQA'=9?PGPBC:' _%=D!"V]2>H% H";NA
M:<B^B;L[8#_1>*X&C]HLSQS81K!+?H*%T@EF#LSFH9M_:V1 #,MFT56P;%B$
ME3C4ZM&?PF07['@F3;PL=L&@U]&Q88'-BFJ4H$,PE*!BEU+IFSJS\,-B1QAL
M794U14=UWN8+M"VF"5BLL@PLFPX20)KK&T!'V['ZS$0Z*)P7*L42LO4!Y0NZ
M!!,OG&.4RV6DPE-4!\&JHY89H=X<S"PSFW2 A XV7%V#1Q VVAAM7]9N.5&0
M@"<A[/0[B5X'*-'Z4%$8O 0>.&/D#2TT)*0'K6&&J!,DBN'G*A5Z/.#V$58<
M_#3NDSW7MU^.8QD^-6NQ4/6+-').)V*YL1EF@_OV_@XS3RDK/'H:)Y,,L)6^
M=8RT@.$\"MM%YWRT:$P#6-JL"7W) -TJ'8\-=J(G,2G%-('1P&$PW6/*-D;;
MI5HCBIC'U>$M9!2 5?8D!VY*V]ATU/,PV.\:G7R61ET8RKU "KD<+U+F>ETH
M5?0=Y_F "NJ(C27P35D+X1@NLY\@,989 6=,=UF&7]1'X*70/@)379A#3$[;
M^\@9YBOY.J_N8#09"W/O& N#WT>3J0E;RD>%XS(6A$QV)_'U(&*,A8^."_<W
M:=_SKNX1#A1!)6"LTL$CJECB<\FOL7GN.\.IPI?9'?CW&[A(JMGTYUI2ZPD9
MOUNG5S"O#%&%[K;VNS'&90JZ FJC/4[?3.B[%6TM[OY#XJJ.;@>[9;XG'OD9
M&O/;,MAX98G-=M:C%J^2N>GRI_;=%Y#^*I=Q?H::@+D7UDGC"QP BX-5+T\"
M_)YRXOW[T;>\W:6O"XKM;J&71UZ/R"B7TT2^Z_5?BSF\L4%L98Q) R3&E&<I
MO$2/Y**3BUHXN="8A3_OS+=04OBWEI!_;F\1Z6G7WYUES>TI4@L07>(.064Z
M[$)/H:OO#S%,\MENQ-NDKQ"-AGBHNP1FDG2.6S:9W^+VH':.M/ <PYVOHVHK
M7IW_K9:?UYX5.#-_P\4_1?:&)510 N:1^:DT+6#==PCL*X? EF^(\*R*]?)Q
MI=!HUDKUM6A^_(CF((OBT=>=T'?XML2=GZQ0;3K]0O.-,5*Q3U,FF#LW6"1/
M7Z,0Y (KX(85'#6JD"XVVM0C2RMB+N>P /75^B8\PZK#OM>U'&B4QG]HP&\C
MO);/PTLJS:<6+H;8Y+C96](O>?E+A@3?T+0T+WVF5WFE4I/YS&>>JOC?17+?
M:'<O[78KL.KH">?YN?/5F#D*2$8']%];\M;R508RO_:YPZLG9M>JC<)Y^18=
ME*N-DU*M<%EJ-LK%>G1B=J7(KW?1YP:F9'WLGJV?J]#O<)PN&Q(V@\IEZ+X9
M5"X%Z@US0G^KZ"(J#\;Y^8. ](9!0. %Z2UK7-;:HH2;0(>.Y: #[';Q.Z-6
MWPKSM3&-+@_*;SRD?:OI)E'Y"6K*%I1NOI[2X)>N14F:-,6RC4J3#8.K;,-@
MYY/6TFV.L_>]]O8'N4[CWJ70:SGE7YJ^1B>VLC#7XSJP=&V^P_5YZJM8VAC^
M=+V^L?__4$L#!!0    ( &,WA%0QDI8)S",  !2!   7    <&QX+3(P,C(P
M-# T>&5X.3ED,2YH=&WM/6ESVT:6?Z77J<Q(M21%4K?H<2TMR1[7^BI9F<Q4
M[9<FT"0Z @$&#8AB?OV^H[O1 "E*=F3-49FJB242Z./=MU[^5[=[F24RBU0L
M_GK]X;V(\ZB:JZP44:%D"9\N=9F(ZWRQD)GXH(I"IZEX7>AXIH0X[0T.>OW>
MZ5&W^^HE+'5NW\FS,W&P=[ W[ ^'8M _.SPY.S@2XP]BYZ?K\UUZ^.+3^?4_
M/E_RII]_>OW^W;EXT=W;^WG_?&_OXOJ"OX#5!^*ZD)G1I<XSF>[M77Y\(5XD
M9;DXV]M;+I>]Y7XO+V9[UU=[23E/#_;2/#>J%Y?QBU<O\1/XKY+QJY=S54H1
M);(PJOS+BY^NWW1/X(E2EZEZ]7+/_<O/3O)X]>IEK&^%*5>I^LN+N2QF.NN6
M^>)LO[\H1_#F'GS=>N:NN]1QF9P-^OT?1PL9QSJ;=5,U+<\&PU[_M/ZLT+.D
M_C#GRYT5*I6EOE6X^I:]Y_!+HFB%_2/X/=@37ERXUZ9Y5G:G<J[3U=F?K_5<
M&?%1+<55/I?9GSO\"?QK5*&G?Q[1TT;_IN!4L&:I[LJN3/4,3H4[C?@09_;N
MD\8F2S[,)$]C^/+R+M$37?[IA\%1?W0*%/)R;P+06CS5T9HGP2_=LK?:P,ZI
M+E=GB8YCE<$#?_KA9-C?'[W<PP>?_AC=25Z6^9Q.8S\A? >_(][PU_Q6%=,T
M7[JS;42[GL^$*:*_O%BD=UWDGOY!_^!.W9V>QH#@0>^7Q>R%D"D0\-M"+A(=
MO7"7B;59I')UIK-49ZH[2?/H9N3(Y+0FD^%);WBX#CM'F?8^0)GP3)-<[6=K
MQR9:T1G<B>_]&_UR=S88361T,ROR*HO/EHDN57O3C6>VYSSN'1_]2 @\K;''
M_VQ:HG'?P>)NY-'@#RPG)D\K.$7 ,.ZL?4<J!Z--NP#>9&DYH<'73P.3[5@?
MAEB_NA#O\UG^*+0?G/2.#S=B_CMQP^]@RC5I&J5*%B!3RF34%JR;&.?)Q5X$
MJ%/%EHNMB;ZF1*#UGE4BM5CX41?:)L@_%WD)K]Z)USJ_3A3(&U65.C)"9K$X
M3[0R6KQ-\XE,Q94LE+C01DD#1QYG&=!WI-!J0*H45\I4:6G$M,CGHDR4&!YT
M/\"&B?B<P!NL*MZ]>R=>C]^//YY?BG-X34>P\'6AX;_Y5'R^^GMWT!^*:5[0
M"M=H:9"= E^^D9-BY?9_8G73@NIQ[W C6 .V_F%*_]M".E&>YL79#\/!\'!X
M:C?$;\XT CP:;4*&O;^IHD@9,ZW2="7 I"%@+ H-FZV$RN)%KA$FF;C1<:96
M8@J(0&81.A,R0FX1$:Q>Y&EGDZ#[AI.]G!0;)?,W+)7E&<C)*> A+X!G8*4J
M7HE;TQ-R)E.C8T"OF( =]]V9YY^%9L<QA>686,WSS)0%6=523.5M7LA)JD29
MI\"1+%N((?5\7F7Y3 '?X$>+(I_J5/WKX1@9V!+STV/Q*Q$F\/^$:O$TZ'O]
M?DRHF\RU,<AUH)NS#%#GQ)91P'VQ2&0Z1<&%NOY[*F.Z('XF'B'OS\=7']Y=
MON^(=Z:0*D4Y2I2U]:77G[Y<?_J(SW;$&.10RL+\H$-W$WN?K^#<9JD+M7>?
M/H$-LZ@G=C[^X\LEOSV>P[TBF9U]?O_W7;%S/?YR23]V@ 4F.E^ $S>7$;T-
MVB'*Y^";@J@#S]60\TF@CM6M2O,%ZH@.LD-<L2#$*\$KL$4$ND7_)NE30$8!
MN)E/="8SDJKN?/ANJ71F["*PPV0E=$F_PXU!'('HA<N=JS2]O'MIJB86"2]H
M@(/]3P>V! I^ 5D#@V.T.>&M5T0MX'C#.MV)Q*O8K86Z6P!9$469E2G5O/.0
M$B90509DB3&BRC3I2?O\FQI\6GSI+7KC'JX'*@(X)I/L:",=@P46)1ZNX!JG
M91+A+F^!HQ9BQ^V/OP%RRCR6*(Q8^\?P>U.8>?7OU/Q"WR))M*V R&G_DK2_
MNI5I!:?*9F*A9G"76A< &TFQ8\4)G&# B\QG>S<SN%(,KK(&<!5P&* &0%.Y
MS,52J1N #Y%-0<=LJQ>Q@Q:%_&TU5[\#G;N>Z\MU8R5F//6\8:/!KA(9.(EI
M1WR^?+M*2>2K# \!$ 32B!0MP:2Y$CN75]>[@-I8%2&M/V;39Y$U:.<.^Z.?
M 4M ,8M4$44CL)UYR(;\K7J84+83"++",J_26*3Z!E>#=V5V0RLT+BX60$8
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M"+H.R1>PT,LHP<,#7ATAP.?(##JK2*QGZP@?P^,E!VB.CP-$XX86LR-Q.&3
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MNJ-P&P@LH^_<6<:EP"0H^Q=\@2\7NRPA$!['^[U]1XBII\QOI$D Q&GO9,B
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MEF9X;A".5>>C@?@%P8+:F_("U'1!]9!MRT)GMWE*":\$Y %\-:-^Q"E!Q*O
M9JD5Y1%:8W;MU.%Z+C$9S;87 3VW#+WAJ:9:U[K=N+D*UDM$-([RCTC?OW6D
M;],?#6I(?N8K:K5CSG*L$DR2,:Y,#,3U'$-V'&X[L\SJ0G)6:)=Z[L;=>9O#
M#T]4F!+V-4B8L;1SNM[;.5WC[7.Z;+XV,%VHJ-GY:6#,TJ"KT;:C=>IS4;&@
MO@&^2#!]!V>R4Z==IB[("M$DOJH /Y7^4B*WA1@QGE'MT,[EA_$N7\H>F*PB
MK)^3;/=(G,UU0]/:Q)@31C8T&-RYW=79ZCJB+F^7LJ*,#HES/*+M-_;5^K;
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M;'@M,C R,C T,#0N>'-D4$L! A0#%     @ 8S>$5)R5K)NB!0  Y3X  !0
M             ( !\ ,  '!L>"TR,#(R,#0P-%]L86(N>&UL4$L! A0#%
M  @ 8S>$5"(R.0FC!   1BH  !0              ( !Q D  '!L>"TR,#(R
M,#0P-%]P<F4N>&UL4$L! A0#%     @ 8S>$5$OEAK 8%0  :)X  !,
M         ( !F0X  '!L>"TR,#(R,#0P-'@X:RYH=&U02P$"% ,4    " !C
M-X14,9*6"<PC   4@0  %P              @ 'B(P  <&QX+3(P,C(P-# T
A>&5X.3ED,2YH=&U02P4&      4 !0!( 0  XT<

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
